These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 7746913)

  • 1. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa.
    Onyebujoh PC; Abdulmumini T; Robinson S; Rook GA; Stanford JL
    Respir Med; 1995 Mar; 89(3):199-207. PubMed ID: 7746913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group.
    Lancet; 1999 Jul; 354(9173):116-9. PubMed ID: 10408487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97.
    Mayo RE; Stanford JL
    Trans R Soc Trop Med Hyg; 2000; 94(5):563-8. PubMed ID: 11132390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis.
    Stanford J; Stanford C; Grange J
    Front Biosci; 2004 May; 9():1701-19. PubMed ID: 14977580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis.
    Huang CY; Hsieh WY
    Hum Vaccin Immunother; 2017 Sep; 13(9):1960-1971. PubMed ID: 28604170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis.
    Dlugovitzky D; Fiorenza G; Farroni M; Bogue C; Stanford C; Stanford J
    Respir Med; 2006 Jun; 100(6):1079-87. PubMed ID: 16278080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial.
    Mwinga A; Nunn A; Ngwira B; Chintu C; Warndorff D; Fine P; Darbyshire J; Zumla A;
    Lancet; 2002 Oct; 360(9339):1050-5. PubMed ID: 12383985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis?
    Stanford JL; Stanford CA; Grange JM; Lan NN; Etemadi A
    Respir Med; 2001 Jun; 95(6):444-7. PubMed ID: 11421500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration.
    Johnson JL; Kamya RM; Okwera A; Loughlin AM; Nyole S; Hom DL; Wallis RS; Hirsch CS; Wolski K; Foulds J; Mugerwa RD; Ellner JJ
    J Infect Dis; 2000 Apr; 181(4):1304-12. PubMed ID: 10753731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, placebo-controlled, 1:1 randomized Phase III clinical trial of Immunoxel honey lozenges as an adjunct immunotherapy in 269 patients with pulmonary tuberculosis.
    Batbold U; Butov DO; Kutsyna GA; Damdinpurev N; Grinishina EA; Mijiddorj O; Kovolev ME; Baasanjav K; Butova TS; Sandagdorj M; Batbold O; Tseveendorj A; Chunt E; Zaitzeva SI; Stepanenko HL; Makeeva NI; Mospan IV; Pylypchuk VS; Rowe JL; Nyasulu P; Jirathitikal V; Bain AI; Tarakanovskaya MG; Bourinbaiar AS
    Immunotherapy; 2017 Jan; 9(1):13-24. PubMed ID: 27868466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 1. Newly-diagnosed pulmonary disease.
    Corlan E; Marica C; Macavei C; Stanford JL; Stanford CA
    Respir Med; 1997 Jan; 91(1):13-9. PubMed ID: 9068812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172).
    Dlugovitzky D; Bottasso O; Dominino JC; Valentini E; Hartopp R; Singh M; Stanford C; Stanford J
    Respir Med; 1999 Aug; 93(8):557-62. PubMed ID: 10542989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis.
    Yang XY; Chen QF; Li YP; Wu SM
    PLoS One; 2011; 6(9):e23826. PubMed ID: 21909406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7).
    Efremenko YV; Butov DA; Prihoda ND; Zaitzeva SI; Yurchenko LV; Sokolenko NI; Butova TS; Stepanenko AL; Kutsyna GA; Jirathitikal V; Bourinbaiar AS
    Hum Vaccin Immunother; 2013 Sep; 9(9):1852-6. PubMed ID: 23782489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis].
    Luo Y;
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Jan; 24(1):43-7. PubMed ID: 11802939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7).
    Butov DA; Efremenko YV; Prihoda ND; Zaitzeva SI; Yurchenko LV; Sokolenko NI; Butova TS; Stepanenko AL; Kutsyna GA; Jirathitikal V; Bourinbaiar AS
    Immunotherapy; 2013 Oct; 5(10):1047-54. PubMed ID: 24088075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological basis for the introduction of immunotherapy with Mycobacterium vaccae into the routine treatment of TB.
    Dlugovitzky D; Stanford C; Stanford J
    Immunotherapy; 2011 Apr; 3(4):557-68. PubMed ID: 21463195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis.
    Johnson JL; Nunn AJ; Fourie PB; Ormerod LP; Mugerwa RD; Mwinga A; Chintu C; Ngwira B; Onyebujoh P; Zumla A
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1348-54. PubMed ID: 15581204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
    Kassim S; Sassan-Morokro M; Ackah A; Abouya LY; Digbeu H; Yesso G; Coulibaly IM; Coulibaly D; Whitaker PJ; Doorly R
    AIDS; 1995 Oct; 9(10):1185-91. PubMed ID: 8519456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.